Sennoside A

Sennoside A

SCHEMBL440792

O=C(O)c1cc(O)c2c(c1)[C@H]([C@H]1c3cc(C(=O)O)cc(O)c3C(=O)c3c(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)cccc31)c1cccc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c1C2=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 4/20 1.00
HKDC1 Q2TB90 3/20 1.00
L3MBTL1 Q9Y468 3/20 1.00
TDP1 Q9NUW8 3/20 1.00
KDM4E B2RXH2 3/20 1.00
MAPT P10636 3/20 1.00
TNNI3 P19429 2/20 1.00
TNNT2 P45379 2/20 1.00
TNNC1 P63316 2/20 1.00
MEN1 O00255 2/20 1.00
CYP3A4 P08684 2/20 1.00
MAPK1 P28482 2/20 1.00
RECQL P46063 2/20 1.00
KMT2A Q03164 2/20 1.00
NPC1 O15118 1/20 1.00
RAB9A P51151 1/20 1.00
LMNA P02545 1/20 1.00
GLA P06280 1/20 1.00
THRB P10828 1/20 1.00
HPGD P15428 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sennoside B SCHEMBL19004132 1.00 USP2 (1.00) USP2HKDC1L3MBTL1TDP1KDM4E
Sennoside B SCHEMBL14478776 1.00 USP2 (1.00) USP2HKDC1L3MBTL1TDP1KDM4E
Sennoside B SCHEMBL15216902 1.00 USP2 (1.00) USP2HKDC1L3MBTL1TDP1KDM4E
Sennoside B SCHEMBL19235654 1.00 USP2 (1.00) USP2HKDC1L3MBTL1TDP1KDM4E
Sennoside B SCHEMBL17430774 1.00 USP2 (1.00) USP2HKDC1L3MBTL1TDP1KDM4E
Sennoside B SCHEMBL19004127 1.00 USP2 (1.00) USP2HKDC1L3MBTL1TDP1KDM4E
Sennoside B SCHEMBL23685626 1.00 USP2 (1.00) USP2HKDC1L3MBTL1TDP1KDM4E
Sennoside B SCHEMBL441194 1.00 USP2 (1.00) USP2HKDC1L3MBTL1TDP1KDM4E
Sennoside B SCHEMBL17131971 1.00 USP2 (1.00) USP2HKDC1L3MBTL1TDP1KDM4E
Sennoside A,B SCHEMBL20822082 1.00 USP2 (1.00) USP2HKDC1L3MBTL1TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021153-A1 TRADITIONAL CHINESE MEDICINE FORMULATION FOR PREVENTING AND TREATING CONSTIPATION-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-C) CENTRE FOR CHINESE HERBAL MEDICINE DRUG DEVELOPMENT LTD (CN) 2026-01-22 US claimed
EP-4681194-A1 ACOUSTIC SENSING AND COMMUNICATION USING A METASURFACE Microsoft Technology Licensing, LLC (US) 2026-01-21 EP claimed
EP-4676473-A2 COMPOSITIONS AND METHODS FOR MODULATING STRESS AND USES THEREOF Brightseed, Inc. (US) 2026-01-14 EP claimed
WO-2025132951-A1 AQUEOUS COMPOSITION WITH A SENNOSIDE AND AT LEAST ONE HYDROTROPE AGENT L'OREAL (FR) 2025-06-26 WO claimed
WO-2025132954-A1 AQUEOUS COMPOSITION WITH A SENNOSIDE AND A WEAK BASE L'OREAL (FR) 2025-06-26 WO claimed
WO-2025132781-A1 COSMETIC COMPOSITIONS COMPRISING SENNOSIDE L'OREAL (FR) 2025-06-26 WO claimed
CN-120189424-A Application of sennoside A in medicine for preventing and/or treating retinal photodamage 浙江大学长三角智慧绿洲创新中心 2025-06-24 CN claimed
CN-120118973-A Acetaldehyde dehydrogenase activity detection kit, detection method and application thereof 浙江大学长三角智慧绿洲创新中心 2025-06-10 CN claimed
EP-4543898-A1 PYRIMIDINE NUCLEOSIDE TREATMENTS The Children's Medical Center Corporation (US) 2025-04-30 EP claimed
CN-113421620-B Based on UPLC-Q-TOF/MSEMethod for carrying out fuzzy recognition on bioactive components with different effects of traditional Chinese medicine by BP neural network correlation analysis of integration effect 陕西中医药大学 2025-04-29 CN claimed
EP-0544886-B1 METHOD OF EXTRACTING SENNOSIDES A, B and A1 MADAUS AG (DE) 1997-09-10 EP claimed
EP-0682665-A4 ANTHRAQUINONE AND ANTHRACENE DERIVATIVES AS INHIBITORS OF THE CELL-ADHESION MOLECULES OF THE IMMUNE SYSTEM. GLYCOMED INC (US) 1996-01-10 EP claimed
EP-0682665-A1 ANTHRAQUINONE AND ANTHRACENE DERIVATIVES AS INHIBITORS OF THE CELL-ADHESION MOLECULES OF THE IMMUNE SYSTEM GLYCOMED INCORPORATED (US) 1995-11-22 EP claimed
US-5412123-A Anthraquinone and anthracene derivatives as inhibitors of the cell-adhesion molecules of the immune system GLYCOMED INCORPORATED (US) 1995-05-02 US claimed
WO-1994018189-A1 ANTHRAQUINONE AND ANTHRACENE DERIVATIVES AS INHIBITORS OF THE CELL-ADHESION MOLECULES OF THE IMMUNE SYSTEM GLYCOMED INCORPORATED (US) 1994-08-18 WO claimed
CN-1088933-A The method of the sennoside that preparation is selected MADAUS AG (DE) 1994-07-06 CN claimed
EP-0544886-A1 METHOD OF EXTRACTING SENNOSIDES A, B and A1. MADAUS AG (DE) 1993-06-09 EP claimed
US-5208151-A Process for the preparation of derivatives of maltooligosaccharides NIHON SHOKUHIN KAKO CO., LTD. (JP) 1993-05-04 US claimed
WO-1993000350-A1 METHOD OF EXTRACTING SENNOSIDES A, B and A1 MADAUS AG (DE) 1993-01-07 WO claimed
US-4402944-A COMPLEMENT INHIBITORS AMERICAN CYANAMID COMPANY (US) 1983-09-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021153-A1 TRADITIONAL CHINESE MEDICINE FORMULATION FOR PREVENTING AND TREATING CONSTIPATION-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-C) VIP, RDX, SI USP2 1567/4885HKDC1 2615/4885L3MBTL1 4657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.